Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Q3 2026 Earnings Presentation
26 slides from Inovio Pharmaceuticals's earnings presentation, Nov 10, 2026
Slide 1: Third Quarter 2026 Financial Results
Third Quarter 2026 Financial Results November 10, 2026
Slide 2: Agenda
Agenda Introduction Jennie Willson, Director, Communications CEO Perspective & Corporate Progress Jacqueline Shea, PhD, President & Chief Executive Officer Approval & Commercial Launch Plans for VOCERYQ Michael Sumner, MBBS, MBA, Chief Medical Officer & Head of Development Steve Egge, MBA, Chief Com
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 4: VOCERYQ Now Approved
VOCERYQ Now Approved Formerly known as INO-3107 Approved to reduce the frequency of surgery in adults with RRP This indication is approved under accelerated approval based on reduction in the frequency of surgical papilloma excisions. Continued approval for this indication may be contingent upon ver
Slide 5: INOVIO's Focus as a Commercial-Stage Company
INOVIO’s Focus as a Commercial-Stage Company Maximize VOCERYQ Execute successful Leverage platform opportunity commercial launch validation and by meeting to generate revenue partnerships to patient needs and drive value for advance pipeline shareholders 5
Slide 6: Clinical Data and Label Details
Clinical Data and Label Details
Slide 7: Multi-Center Clinical Study at 8 Clinical Sites
Multi-Center Clinical Study at 8 Clinical Sites RRP-001 PHASE 1/2 OPEN-LABEL STUDY RRP-002 DURABILITY EXTENSION / FOLLOW-UP Baseline: DAY 0 52 WEEKS 104 WEEKS 156 WEEKS Patients Enrolled 4 Doses of VOCERYQ Completed Study Consented to Follow Up Median Completed Follow Up Follow Up N=32 N=32 N=28 N=4
Slide 8: Previously Published Data for VOCERYQ
Previously Published Data1 for VOCERYQ Potential to meet remaining Meaningful therapeutic benefit critical unmet need PUBLISHED EFFICACY SAFETY DIFFERENTIATED MOA • 50% - 100% reduction in surgeries: • No required minimal residual • Potential ability to treat patients - 72% in YR 1 disease (MRD) sur
Slide 9: Efficacy Endpoint for Approval
Efficacy Endpoint for Approval Based on Reduction in Surgery in 12 Months Following Dosing Completion ANALYSIS ENDS Week 0 3 6 9 Week 61 DOSING 4 doses total Efficacy Analysis Period*: Weeks 9-61 (N=26) (Patients with ≥3 surgeries in the 12 months prior to treatment) *Includes data from weeks 9-52 f
Slide 10: Key Safety Results - Most Adverse Reactions Grade 1 or 2
Key Safety Results - Most Adverse Reactions Grade 1 or 2 Adverse Reactions Occurring in > 5% of Patients in Study RRP-001 (N=32) Adverse Reactions RRP (N=32) n (%) Injection site reaction 11 (34%) Headache 6 (19%) Fatigue 5 (16%) Hypertension 4 (13%) Nausea 2 (6%) Dizziness 2 (6%) 87% were Grade 1;
Slide 11: FDA Alignment on Future Confirmatory Study
FDA Alignment on Future Confirmatory Study Proposed protocol design due to FDA by end of 2026; expected to be finalized by mid-2027 Current general protocol design components: • 50+ adult and pediatric patients with RRP who had 3+ surgeries in 12 months prior to treatment with VOCERYQ TM • Evaluate
Slide 12: Commercial Launch Plans
Commercial Launch Plans
Slide 13: Market Opportunity for VOCERYQ
Market Opportunity for VOCERYQ Large Addressable Patient Population with High Unmet Need 25,000+ prevalent population of adult patients in PRIOR TO VOCERYQ the US with RRP based on ongoing claims data analysis • Most patients managed surgically, every surgery comes with risks and costs Immunotherapy
Slide 14: Potential to Become Preferred First Line Treatment
Potential to Become Preferred First Line Treatment Targets the root cause of RRP to deliver compelling efficacy, reducing the need for surgery Patient-centric approach to treatment that does not require scoping and surgical removal of visible papilloma during dosing window Favorable tolerability pro
Slide 15: Patient Journey – Every Surgery Matters
Patient Journey – Every Surgery Matters 4 doses over 9 weeks Diagnosis Decision to treat (no scoping or surgery (surgery and/or biopsy) with VOCERYQ required during dosing) KOL recommendation: Patient undergoes start immunotherapy initial papilloma as soon as possible* removal VOCERYQ can reduce the
Slide 16: Key Priorities for a Successful Launch
Key Priorities for a Successful Launch Establish Drive awareness Provide seamless patient broad access & adoption & customer support Policies in place for Engage targeted Through the insurers that cover laryngologists and VOCERYQ Support 80% of patients staff to educate on Program make access within
Slide 17: Targeting and Field Deployment
Targeting and Field Deployment Driving rapid awareness, adoption and patient access Highly concentrated market* Field footprint** will cover ~400 Laryngologists treat the vast majority of RRP patients ~90% of RRP patient potential ~80% of patients • 20 territories managed by experienced receive care
Slide 18: Foundation for Long-term Commercial Success
Foundation for Long-term Commercial Success Established infrastructure to enable a successful launch Potential for commercial success • Manufacturing network with current inventory and capacity expected to support • Strength of clinical data launch at least through 2027 • Broad adult indication • VO
Slide 19: VOCERYQ and Platform Potential
VOCERYQ and Platform Potential
Slide 20: VOCERYQ Program Expansion
VOCERYQTM Program Expansion Additional Expansion in treatment international strategies markets 20
Slide 21: Advancing Our Pipeline Strategy
Advancing Our Pipeline Strategy NEAR TERM MID TERM NEXT GEN Commercialization Advancing Innovating of VOCERYQTM Diversified NextGen Clinical Pipeline DNA Medicines 21
Slide 22: Third Quarter 2026 Financial Update
Third Quarter 2026 Financial Update
Slide 23: Financially Positioned for a Successful Product Launch
Financially Positioned for a Successful Product Launch THREE MONTHS NINE MONTHS ENDED SEPTEMBER 30, 2026 ENDED SEPTEMBER 30, 2026 (UNAUDITED) (UNAUDITED) % % 2026 2025 CHANGE 2026 2025 CHANGE Operating expenses $19.8 $21.2 (7%) $60.4 $69.4 (13%) Net loss ($49.2) ($45.5) 8% ($74.9) ($88.7) (16%) Net
Slide 24: Q&A
Q&A
Slide 25: Delivering on the Promise of DNA Medicine
Delivering on the Promise of DNA Medicine Approval of first product, VOCERYQTM, and transition to commercial-stage company Landmark moment for INOVIO and DNA medicine platform Potential to become preferred first-line treatment option based on compelling efficacy, patient-centric treatment regimen &
Slide 26: Thank you.
Thank you. Investors: Media: Peter Vozzo Josephine Galatioto Peter.Vozzo@icrhealthcare.com inoviopr@icrhealthcare.com
INOVIO Pharmaceuticals — Q3 2026 Earnings Presentation on 6ix